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Background: Ganoderma lucidum has been purported as a potent remedy in the treatment and prevention of
several ailments, including hypertension. This study aimed to explore the anti-ACE potential of protein fractions
from the mycelia of G. lucidum.
Methods: Ganoderma lucidum mycelia were cultivated by submerged fermentation in a liquid medium containing
brown sugar and spent brewer’s yeast. Intracellular proteins were fractionated from mycelia crude water extract by
ammonium sulphate precipitation, and their angiotensin converting enzyme inhibitory activity was evaluated. The
potential anti-ACE protein fractions were further separated by RP-HPLC and characterised using proteomics
platforms.
Results: Preliminary result demonstrated that the mycelia crude water extract inhibited ACE at IC50 value of 1.134 ±
0.036 mg/mL. Following protein fractionation and HPLC purification, the presence of highly potential anti-ACE
proteins with the IC50 values less than 200 μg/mL was detected. Characterisation of these proteins demonstrated
the presence of four different antihypertensive-related proteins involved in the regulation of blood pressure
through different mechanisms.
Conclusions: This study suggests that the mycelia of G. lucidum has high potential in lowering blood pressure level
due to the presence of several antihypertensive-related proteins such as cystathionine beta synthase-like protein,
DEAD/DEAH box helicase-like protein, paxillin-like protein, and alpha/beta hydrolase-like protein.
Keywords: ACE inhibitory proteins, Bioactive peptides/proteins, Lingzhi, Hypertension, MALDI-TOF/TOF MSBackground
Hypertension is recognised as a grievous global health
problem due to tremendous increase in the frequency of
hypertensive patients as well as the catastrophic sequela
caused by its occurrence. Current report from the World
Health Organization [1] revealed the predominance of
hypertension in approximately 40% of adults aged 25
and above worldwide. Apparently, the high prevalence
has caused hypertension to emerge as one of the major
contributors to cardiovascular disease (CVD).* Correspondence: hanizaaminudin@um.edu.my
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distribution, and reproduction in any mediumA holistic prevention and treatment is urged in order to
reduce the occurrence of the disease. In essence, practising
a healthy lifestyle is a good way in preventing hypertension
and would be recommended as the first-line therapy.
Nevertheless, in situations where lifestyle modification
alone could not adequately lower the blood pressure, anti-
hypertensive medications will be considered.
The paramount aim in treating hypertension typically is
to bring down the blood pressure to its normal level. The
blood pressure in the human body is regulated by a series
of enzymatic reactions in the renin angiotensin aldoste-
rone system (RAAS). Angiotensin converting enzyme
(ACE) (EC 3.4.15.1) is one of the members of RAAS, and
its wide distribution throughout the body indicates that
ACE plays an important role in that particular system [2].
Catalysis by ACE on angiotensin I produces angiotensind Central Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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smooth muscle cells. Besides, the presence of angioten-
sin II also leads to volume expansion through sodium
and fluid retention. Therefore, the inhibition of ACE
has been viewed as a therapeutic target for the treat-
ment of hypertension.
ACE inhibitors were discovered as bradykinin-poten-
tiating peptides from the venom of the South American
snake Bothrops jararaca, as well as other venomous
snakes. Based on the previous findings, Cushman and
Ondetti developed captopril, which became the first
clinically approved synthetic ACE inhibitor [3]. There
are an array of ACE inhibitor drugs available, including
captopril, enalapril, fosinopril, lisinopril, perindopril,
ramipril, trandolapril, and zofenopril. These ACE inhibi-
tors differ from each other with respect to their molecu-
lar structure, potency, bioavailability, plasma half-life,
and tissue affinity [4].
Consumption of synthetic ACE inhibitors was reported
to bring side effects to humans. The presence of the
sulphydryl binding group was suggested to attribute to
skin rash, taste disturbance, and proteinuria [5]. Earlier
study showed the direct effect of ACE inhibitors towards
the activation of the bradykinin receptor, and the poly-
morphism of the receptor gene was suggested to colligate
with cough [6]. Hence, the divulgence of synthetic ACE
inhibitors’ side effects by clinical trials has inspired scien-
tists to investigate a safer alternative.
Attempts have been made to explore natural products
as cure for hypertension including ACE inhibitory pep-
tides. These peptides have been increasingly acknowl-
edged since they are less expensive and serve safer blood
pressure lowering effect compared to conventional ACE
inhibitor drugs. Hitherto, various ACE inhibitory peptides
have been discovered in food proteins derived from dairy
and marine products, fruits as well as vegetables [7]. In-
creased dietary intake of plant protein was reported to
exert a more beneficial effect on blood pressure compared
to protein from animals [8].
Ganoderma lucidum (Curtis) P. Karst (lingzhi, reishi)
is a well-known medicinal mushroom particularly in
China, Japan, and Korea. For centuries, the fruiting bo-
dies of G. lucidum have been adopted by old folks to
treat various ailments. However, the production of the
fruiting bodies is time-consuming because the cultiva-
tion of basidiocarp requires at least three to five months.
The production of G. lucidum mycelia used as a bio-
resource of peptides is approximately six times faster
than when fruiting bodies are utilised. Therefore, it leads
to the preference of mycelia as an alternative panacea.
Recent research reports create awareness on the health-
improving properties of the mycelia [9] and thus urge the
need for more comprehensive studies. To date, no study
has been conducted to determine if the mycelia proteinsexhibit anti-ACE properties. Hence, the present study
aims to isolate and characterise the peptides/proteins
with promising anti-ACE activity from the mycelia of
G. lucidum.
Methods
Maintenance and cultivation of Ganoderma lucidum
mycelia
Ganoderma lucidum (Curtis) P. Karst culture (KUM50079)
was kindly provided and authenticated by the Mush-
room Research Centre, University of Malaya. It was
maintained on malt extract agar (Oxoid Ltd.) slants at
25°C. During submerged cultivation, the mycelia were
grown in a liquid medium consisting of 2% (w/v) brown
sugar and 1% (w/v) spent brewer’s yeast at pH 5. The
cultivation was performed in 500 mL Erlenmeyer flasks,
each containing 100 mL of media. Ten mycelia plugs
(10 mm diameter) were cut from the periphery of a 12-
day-old culture using a sterile cork borer and were inoc-
ulated into each sterilised flask. The flasks were incu-
bated at room temperature and agitated at 140 rpm
using SK 300 rotary shaker (Lab Companion). Following
seven days of cultivation, the mycelia were harvested.
Mycelia biomass was separated from the broth culture
by employing vacuum filtration (Jeio Tech, Korea) and
washed with a large amount of distilled water. Later on,
the mycelia biomass was freeze-dried (Labconco), and
the dried crude extract was preserved at 4°C.
Preparation of crude mycelial extract
Freeze-dried mycelia (10 mg) were crushed using mortar
and pestle. The crushed sample was dissolved in 200 mL
of distilled water (ratio 1: 20). Extraction was carried out
at a low temperature of 4°C with constant stirring. Sub-
sequently, the water extract was subjected to centrifuga-
tion at 4°C and 5000 rpm for 20 minutes. The pellet
formed was discarded, while the supernatant was kept
for further study.
Fractionation of mycelial proteins by ammonium sulphate
precipitation
Partial purification was carried out by employing ammo-
nium sulphate precipitation method. Salt (11.2 g) was
slowly added to mycelia crude water extract (200 mL)
with gentle stirring on an ice bath. The solution was
centrifuged at 10,000 rpm (4°C) for 15 minutes. The so-
lution was then subjected to gradual increase of salt
(20% to 100%). Pellet obtained was redissolved in a mini-
mum amount of distilled water and later dialysed using
SnakeSkin pleated dialysis tubing with 3,500 Da molecu-
lar weight cutoff (Thermo Scientific). The process was
performed at 4°C for 48 hours with four times buffer
changes. Afterwards, the dialysed proteins were freeze-
dried and stored at -20°C.
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dodecyl sulphate-polyacrylamide gel electrophoresis
(SDS-PAGE) profile
SDS-PAGE analysis for dialysed mycelial proteins (10%
to 100%) was performed based on the discontinuous
buffering system. The protein separation was done on
18% polyacrylamide Tris/HCl gels. The analysis was car-
ried out under reducing condition with the addition of
dithiothreitol (5 μL, 1% (w/v)) to the protein solutions
(15 μL, 1 μg/μL). All samples were heated at 90°C for
5 minutes prior to electrophoresis. Prestained SDS-
PAGE standards broad range molecular weight (Bio-
Rad) was used as the molecular markers. The gel was
stained with silver staining to visualise the protein bands.
Dialysed proteins (10% to 100%) showing similar protein
band profiles were pooled together as fractions and
subjected to ACE inhibitory activity evaluation.
Evaluation of ACE inhibitory activity of mycelial proteins
The ACE inhibitory activity of the protein fractions was
evaluated using ACE Kit-WST (Dojindo, Japan). The in-
hibitory activity was measured by the detection of 3-
hydroxybutyric acid at 450 nm and involved a series of
enzyme reactions. Protein concentration was determined
using Pierce BCA Protein Assay Kit (Thermo Fisher Scien-
tific) and observed spectrophotometrically at 562 nm. Bo-
vine serum albumin was utilised as the standard reference.
Reversed phase HPLC purification of active ACE
inhibitory proteins
Protein fractions having the strongest inhibitory activity
were subjected to reversed phase HPLC (RP-HPLC)
(Shimadzu, Japan). The purification was carried out on
an Atlantis® T3 C18 column; 5 μm particle size, 250 mm ×
4.6 mm (Waters Corporation, Ireland). Fraction A was
purified using elution buffer 5% to 90% acetonitrile for
45 minutes with the flow rate 1.0 mLmin-1. Fraction C
used elution buffer 5% to 90% acetonitrile for 40 minutes
with the flow rate 1.0 mLmin-1. Eluted samples were
monitored using a PDA detector at 220 nm and 254 nm.
Individual HPLC peaks were collected, and acetonitrile
was totally removed under a stream of nitrogen gas.
Later, the samples were freeze-dried and evaluated for
anti-ACE activity as described earlier.
Identification of protein components in active HPLC
eluted peaks by SDS-PAGE and MALDI TOF/TOF MS
HPLC peaks with potent ACE inhibitory activity were fur-
ther separated using SDS-PAGE. Protein bands from SDS-
PAGE gel were excised and subjected to in-gel tryptic
digestion (6 ng/μL, 37°C overnight). Digested samples
were then desalted using Zip Tip (C18) (Millipore) and
analysed using 4800 Plus MALDI TOF/TOF MS (Ap-
plied Biosystems) [10] combined with Mascot databasesoftware (available at www.matrixscience.com). Unmatched
masses from the Mascot database search were further
analysed by an alternative protein identification tool, Pro-
Found (available at http://prowl.rockefeller.edu/prowl-cgi/
profound.exe) using the following parameters: taxonomy
category - fungi, protein mass range - 0 kDa to 100 kDa,
protein pI range - 3 to 10, one missed cleavage site, charge
state of MH+, mass tolerance between 0.5 Da to 1.15 Da.Statistical analysis
Data analysis was performed using Minitab statistical
software (Minitab Incorporation, USA). The effect of
ACE inhibitor on the activity of ACE was tested by one-
way ANOVA. Means were accepted as significantly dif-
ferent at 95% confidence level (P < 0.05).Results and discussion
In the present study, preliminary evaluation revealed
that the mycelia crude water extract actively inhibited
ACE activity with the IC50 value of 1.134 ± 0.036 mg/mL
compared to broth extract (data not shown). IC50 was
defined as the concentration of sample that inhibited
50% of ACE activity under the experimental conditions.
The ACE inhibitory potential of G. lucidum mycelia was
found to be approximately 1.82-fold stronger when com-
pared to Lyophyllum decastes mycelia (IC50 = 1.637 ±
0.057 mg/mL) [11]. The results revealed the importance
of mycelia as the source of ACE inhibitors that can be
obtained by liquid fermentation.
In order to track down the responsible proteins for the
inhibitory activity, the crude water extract was subjected
to protein purification, first, by using salting-out method.
Based on the salt saturation, ten mycelial proteins were
obtained (10% to 100%). Upon visualisation of SDS-PAGE
gel, fractions that shared similar protein band profiles
were pooled and grouped together, resulting in five frac-
tions: fraction A (10%-40% salt saturation), fraction B
(50%-60% salt saturation), fraction C (70% salt saturation),
fraction D (80%-90% salt saturation) and fraction E (100%
salt saturation).
ACE inhibitory activity was measured for all fractions
at a concentration of 200 μg/mL (Figure 1A). Fractions A
(69.92% ± 2.71%, IC50 = 120 ± 2.65 μg/mL), B (68.54% ±
0.49%, IC50 = 125 ± 4.62 μg/mL), and C (66.08% ± 1.71%,
IC50 = 109 ± 1.53 μg/mL) showed more than 65% inhib-
ition percentage. Since fraction C demonstrated the stron-
gest inhibition and gave the lowest IC50 value among all, it
was selected to be further purified. Fraction A was also
considered for further protein purification step. This was
due to its properties of being the more hydrophobic than
others and concurrently showing potent inhibitory activity.
Polarity of inhibitor seemed to have a notable effect on
ACE inhibition as the presence of inhibitor possessing
Figure 1 ACE inhibitory activity of (A) protein fractions at a concentration of 200 μg/mL and (B) RP-HPLC peaks evaluated at a
concentration of 25 μg/mL. Values are expressed as mean ± SEM of three replicate determinations. Mean values with different lowercase letters
(a-d) indicate significant difference at P < 0.05.
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to contribute to high ACE inhibitory activity [12].
Both fractions A and C were further separated by RP-
HPLC on a C18 column. Figure 2 represents the super-
imposed HPLC profiles of separated proteins acquired at
wavelengths 220 nm and 254 nm. Eluted peaks derived
from protein fractions A (Figure 2A) and C (Figure 2B)
are tagged as A1-A6 and C1-C7, respectively. The eva-
luation of ACE inhibitory activity at 25 μg/mL samples
demonstrated that only C3 (67.94% ± 1.04%), C4 (57.96% ±
0.64%), and C5 (60.06% ± 3.37%) showed more than 50%
inhibition (Figure 1B).
The IC50 values determined for these peaks were 10 ±
0.15, 18 ± 1.62, and 12.5 ± 1.71 μg/mL, respectively (Table 1).
The results indicated that separated proteins exhibited
stronger inhibitory activity than a whole protein. The in-
hibitory effect was stronger compared to the naturally oc-
curring ACE inhibitors discovered from other medicinal
mushrooms such as Grifola frondosa (IC50 = 97 μg/mL),
Tricholoma giganteum (IC50 = 40 μg/mL), and Pholiota
adiposa (IC50 = 44 μg/mL) [13-15].Conversely, peaks from fraction A demonstrated
meagre inhibitory rate. This result could suggest syner-
gistic interaction between proteins in fraction A since
they effectively inhibited ACE activity as a group but
the inhibition effect became insignificant once they
were separated through chromatography. Apparently,
the synergistic effect of ACE inhibitory peptides had
been reported by other studies [16].
Protein profiling of the potent anti-ACE HPLC peaks
(C3-C5) was performed by SDS-PAGE (Figure 3), and
distinct protein bands observed were subjected to pro-
tein identification using a proteomic tool, MALDI TOF/
TOF MS. In MALDI, the protein samples were digested
by trypsin, and the masses of all peptides generated were
shown in MS spectrum. The search for matched protein
was later done by using peptide mass fingerprinting
(PMF) method in which peptides’ masses attained from
MALDI were incorporated as the fingerprint in Mascot
database. It appeared that the score for every sample
spot was low and not significant at the 0.05 level of con-
fidence, and thus revealed that the unknown proteins
Figure 2 RP-HPLC profile of (A) protein fraction A and (B) protein fraction C. Numbers 1-7 indicate the peaks that were collected for further
analysis. Indicates wavelength at 220 nm; indicates wavelength at 254 nm.
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Mascot program.
An alternative PMF program, ProFound, had been
adopted to identify the unknown proteins since the re-
sults provided by Mascot were less favourable. ProFound
was selected after considering its good performance in
identifying proteins [17]. The peptides’ masses obtained
from MALDI TOF/TOF MS were submitted to the Pro-
Found program, and intriguingly, four antihypertensive-
related proteins were recognised as the best matched
protein candidate (Table 2). Each of the identified pro-
teins has a probability of approximately 1 and this valuereferred to the value calculated according to Bayesian
probability. It was suggested that protein candidate hav-
ing a probability value close to 1 was likely to be the cor-
rect protein [18].
In addition, the quality of the search result was also
reported in which it was represented in the form of an
estimated Z score. Z scores of more than 1.645 were
considered significant (P < 0.05). Each of the putative
proteins was found to have a high Z score, which was
2.43, indicating the respective search result having 99%
probability of an accurate match. Apparently, it revealed
that unambiguous protein identification was achieved
Table 1 IC50 of ACE inhibitory proteins from
G. lucidum mycelia
Protein source IC50 values (μg/mL)
a
Crude water extract 1134 ± 36
Ammonium sulphate precipitation
Fraction A 120 ± 2.65
Fraction C 109 ± 1.53
RP-HPLC
C3 10.0 ± 0.15
C4 18.0 ± 1.62
C5 12.5 ± 1.71
aData are expressed as mean ± SD of three replicate determinations for each
purification step.
Figure 3 SDS-PAGE profile for HPLC peaks C3, C4, and C5.
Identified antihypertensive-related proteins are marked in boxes with
alphabetical a-b.
Mohamad Ansor et al. BMC Complementary and Alternative Medicine 2013, 13:256 Page 6 of 8
http://www.biomedcentral.com/1472-6882/13/256using the ProFound tool. These proteins were involved
in the regulation of blood pressure through various
mechanisms. Hence, the unknown proteins were charac-
terised as cystathionine beta synthase-like protein (C3-a),
DEAD/DEAH box helicase-like protein (C3-b), paxillin-
like protein (C4-a), and alpha/beta hydrolase-like protein
(C5-a) (Figure 3).
Cystathionine beta synthase (CBS) is involved in the
transsulfuration pathway and is crucial for the produc-
tion of hydrogen sulfide (H2S). CBS might also be in-
volved in blood pressure control, in which it is assumed
to inhibit ACE activity by interfering with Zn2+ in the
active centre of ACE. Findings from Proudfoot and col-
leagues showed that CBS has been recognised to possess
metal ions binding properties due to the presence of the
Zn ribbon domain [19]. In an earlier study, this Zn rib-
bon domain was suggested to possess the ability to bind
zinc [20]. Zinc cofactor is a prominent component for
the enzyme catalysis, and therefore, the interaction of in-
hibitor with Zn2+ at the active centre could disrupt ACE
activity. Inactivation of ACE resulted in the decreased
production of vasoconstrictor substance, angiotensin II.
With regard to the present results, we assumed that
the matched homology of CBS-like protein to that of
CBS might include protein sequences of the Zn ribbon
domain. Further work is required to validate whether
CBS-like protein inhibits ACE by interacting with Zn2+
at the enzyme’s active centre. A study on structure-
activity relationship is a good approach to justify the
postulation [21].
The second related antihypertensive protein belongs to
the DEAD/DEAH box helicase family. DEAD/DEAH box
helicase is commonly involved in cellular activities. Re-
cently, DEAD/DEAH box helicase was suggested to ex-
hibit antihypertensive effect through the regulation of
cardiac cellular activities instead of RAAS [22]. According
to Liu and Olson, cardiac helicase activated by MEF2 pro-
tein (CHAMP), which belongs to DEAD box proteins, had
shown to suppress the growth of cardiomyocyte in cardiac
hypertrophy [23]. CHAMP demonstrated antihypertrophic
activity by inhibiting proliferation through general cell cycle
machinery and was characterised by the up regulation of
the cell cycle inhibitor p21CIP1. The inhibitory activity
prompted the regression of cardiac hypertrophy and thus
recovered diastolic function and coronary flow reserve [24].
The recovery of the blood pressure and flow advanta-
geously contributed to blood pressure lowering effect.
Based on our result, DEAD/DEAH box helicase-like
protein might be the responsible protein for the ACE in-
hibitory activity, and at the same time, it might also
demonstrate hypotensive effect via cellular mechanism.
This synergistic effect may bring considerable success in
treating hypertension in the future. A caution, of course,
is that the thorough mechanism of DEAD/DEAH box













1.00e + 000 2.43 29 49.0
DEAD/DEAH
box helicase
1.00e + 000 2.43 19 43.7
Paxillin 1.00e + 000 2.43 23 46.8
Alpha/beta
hydrolase
1.00e + 000 2.43 18 37.1
aValue is calculated according to Bayesian probability.
bThe score reflects the quality of the search result in which it indicates
measure of the confidence for ProFound database. Z score of 2.43 correlated
to a false-positive rate of 1%.
cSequence coverage is defined as the ratio of the length of the protein
sequence covered by the matched peptides to the whole protein sequence.
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sion. Thus, a more detailed investigation on the struc-
tural and pharmacological properties is suggested to be
carried out.
The third antihypertensive-related protein is paxillin. In
general, paxillin serves primary functions in the signalling
pathway and cell motility due to the presence of multi-
domain bindings [25]. Since paxillin lacks identifiable en-
zymatic activity, it was suggested that paxillin plays a
major role as an adaptor molecule that interacts with
regulatory proteins. Intriguingly, paxillin has been found
to associate with the lowering blood pressure ability
through the regulation of the vascular smooth muscle.
Positioned at the dense plaques of the smooth muscle
tissue, paxillin acts as the signalling protein mediated
actin cytoskeleton remodelling process [26]. Polymerisa-
tion and depolymerisation of the actin filaments resulted
in the contraction and relaxation of the vascular smooth
muscle. The vasodilation of the vascular smooth muscle
has been understood to trigger blood pressure reduction
in hypertensive patients. Thus, paxillin mediated the ac-
tion of actin cytoskeleton on blood pressure by promot-
ing the relaxation of the smooth muscle [27].
Paxillin-like protein might be the significant protein
that contributed to the potent anti-ACE activity. While
exhibiting partial homology with paxillin, we assumed
that paxillin-like protein might induce the vasodilation
of the vascular smooth muscle. It is anticipated that this
action will be additive to the ACE inhibitory activity of
paxillin-like protein and may possibly provide a benefi-
cial response beyond antihypertension treatments de-
scribed to date. Further studies are needed to resolve
these and other possibilities.
The fourth antihypertensive-related protein is alpha/beta
hydrolase. Current study has discovered the contribution
of alpha/beta hydrolase protein in blood pressure regula-
tion through the involvement of soluble epoxide hydrolase
(sEH) [28]. Their data was in agreement with the findingsfrom Yu and coworkers in which antihypertensive effect
was observed following sEH inhibition [29].
Apparently, inhibition on sEH activity demonstrated a
reduction in blood pressure and has been the target for
treating hypertension. Inhibitory activity on sEH resulted
in increased epoxyeicosatrienoic acids (EET) level and
decreased dihydroxyeicosatrienoic acids (DHET) level.
Accordingly, blood pressure lowering event could be
explained by the increased release of EET that potentiated
a vasorelaxant response [30]. EET acts as an endothelium-
derived hyperpolarising factor where it induced the vaso-
dilation of the vascular smooth muscle.
In our study, alpha/beta hydrolase-like protein was
expected to exert anti-ACE properties, and the detailed
mechanism of the inhibition still remained unclear. It
was speculated that alpha/beta hydrolase-like protein
might also restore blood pressure level by acting as an
alpha/beta hydrolase inhibitor. On the account that sEH
inhibition could reduce inflammation, it is anticipated
that alpha/beta hydrolase-like protein might provide
synergistic effects in hypertensive patients. The under-
standing of alpha/beta hydrolase-like protein action is
far from complete, and it is critical to perform an in-
depth investigation.
Conclusions
Ganoderma lucidum has drawn folk’s attention in im-
proving health status in which it could ameliorate ail-
ments and lessen diseases risk. In this study, we have
revealed the ability of G. lucidum mycelia in lowering
blood pressure level through the inhibition of ACE activ-
ity. Following purification and identification, we have
discovered four promising antihypertensive-related pro-
teins which are cystathionine beta synthase-like protein,
DEAD/DEAH box helicase-like protein, paxillin-like
protein, and alpha/beta hydrolase-like protein. These
proteins (derived from edible mushrooms) are suggested
to have a lesser possibility to exert adverse side effects
and hence can be a good alternative to conventional an-
tihypertensive drug treatment. This seems to have a re-
markable positive impact on public health across the
globe. All in all, this work had emphasised on in vitro
ACE inhibitory activity, HPLC purification, and identifi-
cation of the potential antihypertensive-related proteins
by proteomics platforms. Further isolation for pure ACE
inhibitor, elucidation of the relationship between ACE
inhibitor’s structure and activity, and in vivo studies are
warranted to ensure its application as a safe alternative
to antihypertensive treatment for humans.
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